1. Show article details.

    Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020

    GlobeNewswire – 7:00 AM ET 08/06/2020

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020 at 1:00 p.m. ET.

  2. Show article details.

    BRIEF-Agios Reports Business Highlights And Second Quarter 2020 Financial Results

    Reuters – 8:44 AM ET 07/30/2020

    Agios Pharmaceuticals Inc (AGIO): * AGIOS REPORTS BUSINESS HIGHLIGHTS AND SECOND QUARTER 2020 FINANCIAL RESULTS. * SECOND QUARTER TIBSOVO NET REVENUE OF $27.6 MILLION. * REITERATES 2020 TIBSOVO NET U.S. REVENUE GUIDANCE OF $105-115 MILLION.

  3. Show article details.

    Agios Reports Business Highlights and Second Quarter 2020 Financial Results

    GlobeNewswire – 7:00 AM ET 07/30/2020

    – Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million – – Significant Clinical Progress for First-in-Class PKR Activator Mitapivat: Established Proof-of-Concept in Sickle Cell Disease; Presented Phase 2 Data in α- and β-Thalassemia; Pivotal Programs to be Initiated in 2021 – – $255 Million Sale...

  4. Show article details.

    Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020

    GlobeNewswire – 7:01 AM ET 07/16/2020

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, July 30, 2020 at 8:00 a.m. ET to report its second quarter 2020 financial results and other business highlights.

  5. Show article details.

    Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020

    GlobeNewswire – 4:01 PM ET 06/17/2020

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020 at 9:00 a.m. ET.

  6. Show article details.

    BRIEF-Agios And Royalty Pharma Announce $255 Mln Purchase Agreement For IDHIFA Royalty

    Reuters – 6:41 AM ET 06/12/2020

    Agios Pharmaceuticals Inc (AGIO): * AGIOS AND ROYALTY PHARMA ANNOUNCE $255 MILLION PURCHASE AGREEMENT FOR IDHIFA® ROYALTY. * AGIOS PHARMACEUTICALS (AGIO) - RETAINS RIGHT TO RECEIVE $25 MILLION PAYMENT UPON ACHIEVEMENT OF A SPECIFIED EX-U.S. COMMERCIAL MILESTONE EVENT. * AGIOS PHARMACEUTICALS (AGIO) - CO HAS SOLD ITS TIERED, SALES-BASED ROYALTY RIGHTS ON WORLDWIDE NET SALES OF BRISTOL MYERS SQUIBB'S IDHIFA.

  7. Show article details.

    Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty

    GlobeNewswire – 6:30 AM ET 06/12/2020

    – Royalty Pharma Acquires Rights to Agios’ Royalty on IDHIFA® Worldwide Net Sales and Outstanding Regulatory Milestone Payments – Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, and Royalty Pharma today announced that Agios has sold its tiered, sales-based royalty rights on worldwide net sales of Bristol Myers Squibb’s IDHIFA®...

  8. Show article details.

    Agios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease

    GlobeNewswire – 2:30 AM ET 06/12/2020

    – 5 of 8 Efficacy Evaluable Patients Achieved a Hemoglobin Increase of ≥1.0 g/dL From Baseline – – Safety Profile Consistent with Previously Published Phase 2 Data for Mitapivat in Patients with Pyruvate Kinase Deficiency or Expected in the Context of Sickle Cell Disease – – Pharmacodynamics and Biomarker Data Support Mitapivat’s Proposed Mechanism of Action – – Data Support A...

  9. Show article details.

    Agios First-in Class PKR Activator Mitapivat Demonstrates Sustained Hemoglobin Responses in Non-transfusion-dependent α- and β-Thalassemia in Phase 2 Study

    GlobeNewswire – 2:30 AM ET 06/12/2020

    – Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 12 of 13 Evaluable Patients, Including 4 of 4 α-Thalassemia Patients, During Weeks 4-12 – – 7 of 8 Evaluable Patients Achieved Sustained Hb Response During Weeks 12-24 – – Thalassemia Pivotal Development Plan Expected to be Finalized by Year-End 2020 and Initiated in 2021 – – Company to Host Investor Webcast...

  10. Show article details.

    BRIEF-Thermo Fisher To Co-Develop A Global Companion Diagnostic For Low-Grade Glioma With Agios Pharmaceuticals

    Reuters – 7:37 AM ET 06/09/2020

    Thermo Fisher Scientific (TMO): * Thermo Fisher Scientific (TMO) - TO CO-DEVELOP A GLOBAL COMPANION DIAGNOSTIC FOR LOW-GRADE GLIOMA WITH AGIOS PHARMACEUTICALS. * THERMO FISHER - AGREEMENT WITH AGIOS CALLS FOR IDENTIFYING IDH GENE MUTATIONS USING ONCOMINE PRECISION ASSAY AND ION TORRENT GENEXUS SYSTEM. * THERMO FISHER SCIENTIFIC INC (TMO) - WILL RETAIN RIGHTS TO COMMERCIALIZE TEST GLOBALLY UNDER DEAL WITH AGIOS.

  11. Show article details.

    BRIEF-Agios Announces FDA Orphan Drug Designation Granted To Mitapivat For Treatment Of Thalassemia

    Reuters – 4:08 PM ET 06/08/2020

    Agios Pharmaceuticals Inc (AGIO): * AGIOS ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO MITAPIVAT FOR TREATMENT OF THALASSEMIA Source text for Eikon: Further company coverage:

  12. Show article details.

    Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia

    GlobeNewswire – 4:01 PM ET 06/08/2020

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company’s first-in-class pyruvate kinase-R activator mitapivat for the treatment of patients with thalassemia.

  13. Show article details.

    BRIEF-Agios Pharma Says Vorasidenib Demonstrated Prolonged Disease Control, Encouraging Preliminary Activity

    Reuters – 8:31 AM ET 05/29/2020

    Agios Pharmaceuticals Inc (AGIO): * AGIOS PHARMA -VORASIDENIB DEMONSTRATED PROLONGED DISEASE CONTROL, ENCOURAGING PRELIMINARY ACTIVITY WITH MEDIAN PROGRESSION-FREE SURVIVAL OF 31.4 MONTHS. * Agios Pharmaceuticals Inc (AGIO) - VORASIDENIB DEMONSTRATED A FAVORABLE SAFETY PROFILE AT DOSES BELOW 100MG CONSISTENT WITH PREVIOUSLY REPORTED DATA Source text for Eikon: Further company coverage:

  14. Show article details.

    Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma

    GlobeNewswire – 8:00 AM ET 05/29/2020

    – Vorasidenib Demonstrated Prolonged Disease Control and Encouraging Preliminary Activity with Median Progression-free Survival of 31.4 Months – – Vorasidenib Demonstrated a Favorable Safety Profile at Doses Below 100mg Consistent with Previously Reported Data – – Registration-enabling Phase 3 INDIGO Trial of Vorasidenib Enrolling Patients with IDH-mutant Grade 2 Residual or Recurren...

  15. Show article details.

    Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

    GlobeNewswire – 7:00 AM ET 05/19/2020

    – TIBSOVO® Is the First and Only IDH1 Inhibitor to Be Evaluated in a Phase 3 Clinical Trial for IDH1-Mutant Cholangiocarcinoma – Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that The Lancet Oncology has published data from its global Phase 3 ClarIDHy study of TIBSOVO® in previously treated cholangiocar...

  16. Show article details.

    Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress

    GlobeNewswire – 9:41 AM ET 05/14/2020

    – Data Supporting Utility of TIBSOVO® in AML and MDS Also Accepted for Presentation – – Agios to Host Investor Webcast on June 12 at 7:30 a.m. ET – Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that mitapivat and ivosidenib clinical data will be presented at the European Hematology Association Annual Congress...

  17. Show article details.

    Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting

    GlobeNewswire – 5:01 PM ET 05/13/2020

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that vorasidenib and ivosidenib clinical data will be presented at the American Society of Clinical Oncology Annual Meeting being held virtually May 29-31, 2020.

  18. Show article details.

    Agios to Present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020

    GlobeNewswire – 7:00 AM ET 05/12/2020

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020 at 3:40 p.m. ET.

  19. Show article details.

    Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations and COVID-19 Response

    GlobeNewswire – 7:00 AM ET 04/30/2020

    – First Quarter TIBSOVO® Net Revenue of $22.7 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million – – New Clinical Data from Mitapivat in Thalassemia Accepted for Presentation at the European Hematology Association Annual Congress in June – – Proof-of-Concept Decision for Mitapivat in Sickle Cell Disease on Track for Mid-2020; Data to be Submitted for Present...

  20. Show article details.

    Agios to Webcast Conference Call of First Quarter 2020 Financial Results on April 30, 2020

    GlobeNewswire – 7:00 AM ET 04/16/2020

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, April 30, 2020 at 8:00 a.m. ET to report its first quarter 2020 financial results and other business highlights.

Page:

Today's and Upcoming Events

  • Oct
    29

    AGIO to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Jul
    30

    AGIO announced Q2 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.